title: Does concomitant diabetes affect treatment responses in overactive bladder patients?
abstract: OBJECTIVE
  To compare the efficacy and tolerability of a muscarinic receptor antagonist, darifenacin, in the treatment of overactive bladder (OAB) patients with concomitant diabetes as compared with those without comorbidities.
  
  
  METHODS
  Post hoc exploratory analysis of a published, large, non-interventional study in OAB patients treated with darifenacin including 532 diabetics and 1315 controls. Associations of diabetes with treatment responses were evaluated by multiple regression models.
  
  
  RESULTS
  Diabetics (largely type 2 patients) and controls differed in baseline age, body weight, duration of OAB symptoms and presence of co-medications. However, they exhibited similar OAB symptom episode frequency and problem rating and received similar starting doses of darifenacin. Presence of diabetes was associated with a significantly smaller reduction of OAB symptoms, but the effect attributable to diabetes was small relative to the overall treatment response. The presence of diabetes was not associated with differences in tolerability.
  
  
  CONCLUSIONS
  We conclude that a muscarinic receptor antagonist has comparable efficacy and tolerability in the treatment of OAB patients with and without concomitant diabetes.
authors.affiliation: Praxisklinik Urologie Rhein-Ruhr, Mülheim, Germany.
authors.forename: T
authors.initials: T
authors.lastname: Schneider
authors.forename: D
authors.initials: D
authors.lastname: Marschall-Kehrel
authors.forename: J-U
authors.initials: JU
authors.lastname: Hanisch
authors.forename: M C
authors.initials: MC
authors.lastname: Michel
mesh_terms: D001572:Benzofurans / Q000627:therapeutic use*; D048909:Diabetes Complications / Q000150:complications*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D018727:Muscarinic Antagonists / Q000627:therapeutic use*; D053158:Nocturia / Q000209:etiology; D011759:Pyrrolidines / Q000627:therapeutic use*; D012044:Regression Analysis; D016896:Treatment Outcome; D001745:Urinary Bladder Diseases / Q000209:etiology; D053201:Urinary Bladder, Overactive / Q000150:complications / Q000188:drug therapy*; D014549:Urinary Incontinence / Q000209:etiology
chemical_list: D001572:Benzofurans; D018727:Muscarinic Antagonists; D011759:Pyrrolidines; C101207:darifenacin